Opinions
Elizabeth Dater
Covance Inc
CVD-N
TOP PICK
Dec 17, 2004
Given with what's going on with Vioxx and Cellebrex, this company is very important as the FDA will be asking for lengthier testing on these areas. Looks on this as a fabulous growth story.
$38.970
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
TOP PICK
Largest company in the area of contract research for pharmaceuticals. They do drug trials and research for the large pharmaceutical and biotech companies. Had consistently traded at 25X-30X earnings but are now at 11X earnings. Great growth prospects ahead. Think they can grow at 15%-20% a year starting in 2010.
biotechnology
pharmaceutical
Advertising